# Neurotech Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurotech-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Lincolnshire, US
- Website: www.neurotechusa.com
- Total disclosed funding: $40M
- Latest round: Series F (Apr 30, 2014)
- Investors on record: 13

## About

Neurotech Pharmaceuticals, Inc. focuses on developing innovative therapies for chronic eye diseases, utilizing its advanced Encapsulated Cell Therapy platform to improve patient outcomes in the field of ophthalmology.Neurotech Pharmaceuticals, Inc. specializes in developing therapies for chronic eye diseases. The company is headquartered in Lincolnshire, US. Rich Small serves as the CEO. The firm raised USD 5.05 million in Series F funding on April 30, 2014, from Versant Ventures and other investors, bringing the total amount raised to USD 5.05 million. The company's current valuation is USD 52.823 mn.Neurotech Pharmaceuticals, Inc. specializes in the development of innovative therapies aimed at addressing chronic eye diseases, primarily through its Encapsulated Cell Therapy (ECT) platform. The core offering of the company is its ECT, designed to release Ciliary Neurotrophic Factor (CNTF), which protects retinal photoreceptors from degeneration. This therapy targets Macular Telangiectasia (MacTel) Type 2, a condition that progressively diminishes central vision. Neurotech aims to enhance the quality of life for patients with MacTel by providing effective treatment options. The company's products are marketed in North America and Europe, serving healthcare providers, ophthalmologists, and patients with chronic retinal conditions.Neurotech Pharmaceuticals generates revenue through partnerships with healthcare institutions and potential direct sales of its therapies to medical providers. The company engages in business-to-business transactions, collaborating with clinics and hospitals to facilitate the distribution of its Encapsulated Cell Therapy products. While specific pricing plans are not disclosed, the revenue model likely involves agreements with upfront payments, ongoing royalties based on usage, or subscription-based access to treatment programs for healthcare providers.Neurotech Pharmaceuticals plans to utilize the USD 5.05 million raised in Series F funding to further develop its product offerings and expand its market reach. The company is expected to continue designing therapies that enhance treatment for chronic eye diseases. While specific new products and their release dates have not been disclosed, the firm aims to explore expansion into new geographic regions, including additional markets within Europe and North America, by the end of 2015.

## Funding rounds

- Series F, Apr 30, 2014, $5M — Versant Ventures
- Series B, Nov 16, 2006, $35M — Atlas Venture, Burrill & Company, Versant Ventures, Excalibur Fund Managers, Mayflower Group, IRIS, Amundi Alpha Associates AG, SV Health Investors, NMT Capital, Omega Funds, Seven2, Pound Capital, Merlin Biosciences Fund Ltd

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series B
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B, Series F
- Excalibur Fund Managers (https://capitalatlas.ai/funds/excalibur-fund-managers) — Series B
- Mayflower Group (https://capitalatlas.ai/funds/mayflower-group) — Series B
- IRIS (https://capitalatlas.ai/funds/iris) — Series B
- Amundi Alpha Associates AG — Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B
- NMT Capital (https://capitalatlas.ai/funds/nmt-capital) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Seven2 (https://capitalatlas.ai/funds/seven2) — Series B
- Pound Capital (https://capitalatlas.ai/funds/pound-capital) — Series B
- Merlin Biosciences Fund Ltd — Series B